AWY0
Research AWY0 on Bullrun: market cap EUR 761.21K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAWY0
- ExchangeF
- CountryAustralia
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 761.21K
- Financial periodFY2025
- Net income-AUD 14.92M
- Free cash flow-AUD 15.65M
Valuation Snapshot
latest market cap is EUR 761.21K.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -AUD 14.92M | -AUD 15.65M | n/a | -0.01 | AUD 10.17M | AUD 25.87K | AUD 10.00M |
| FY2024 | n/a | -AUD 11.92M | -AUD 10.12M | n/a | -0.01 | AUD 11.87M | AUD 39.87K | AUD 9.36M |
| FY2023 | n/a | -AUD 11.38M | -AUD 8.18M | n/a | -0.02 | AUD 10.97M | AUD 142.10K | AUD 9.98M |
| FY2022 | n/a | -AUD 5.81M | -AUD 7.81M | n/a | -0.01 | AUD 19.23M | AUD 227.40K | AUD 21.14M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-29 | EUR 761.21K | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About AWY0
Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia. Its products pipeline includes HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed phase I clinical trial to treat to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is AWY0's market cap?
AWY0's market capitalization is EUR 761.21K.
What does AWY0 do?
Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia. Its products pipeline includes HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed phase I clinical trial to treat to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.